Ramamoorthy Nagasubramanian, MD

Hematology/Oncology

Primary Office

Nemours Children's Hospital, Florida Nemours Children's Hospital, Florida 6535 Nemours Parkway Orlando, FL 32827 Appointment: (407) 650-7715

Other Offices

Get to Know Me

I was a timid, but curious child who wanted everything I did to be perfect. I aspired to become an engineer like my father and attended school 1,400 miles away and was homesick. To be closer to home, I applied and was accepted to a medical school in my hometown. I took the opportunity seriously and wanted to be a role model to others in my family.

Why I Treat Children

Growing up in India, I was moved by the severity of malnutrition and poverty of children in India. I thought by being a pediatrician, I could serve as an advocate for these children and help change the cycle by giving families resources and avenues to help them raise healthier children.

What I'm Passionate About

As a clinician, I feel completely obligated to give my patients the best treatment possible, to use strong clinical judgment. This is what moves me. At times, it’s difficult. Even though we’ve made great progress and we help many kids, there are some we can’t help. I see a challenge every time there’s a failure, and that inspires me, too.

How I Try to Make A Difference

I was brought up to believe in giving back to the community. It’s what keeps me going and how I practice medicine.

Education & Training

Fellowship

  • Clinical Pharmacology - University of Chicago Hospitals, 2003
  • Pediatric Hematology/Oncology - University of Chicago Hospitals, 2002
  • Pediatric Hematology/Oncology - University of Chicago Hospitals, 1996

Internship

  • Rotating - Kilpauk Medical College, Madras, India, 1989

Residency

  • Pediatrics - University of Chicago Hospitals, 1995
  • Pediatric Hematology/Oncology - Apollo Hospitals - India, 1993

Medical/Dental School

  • MD - Madras Medical College, 1989

Board Certifications

  • American Board of Pediatrics/General Pediatrics
  • American Board of Pediatrics/Pediatric Hematology-Oncology

Awards & Recognition

  • 2014 Best Doctors in America
  • 2013 Best Doctors in America
  • 2012 America's Top Oncologists
  • 2011 Best Doctors in America
  • 2010 Best Doctors in America
  • 2009 Best Doctors in America

Insurance Accepted

  • Aetna Better Health FL Medicaid and Healthy Kids
  • Aetna HMO/POS/PPO/EPO
  • AmeriHealth Caritas Florida (FKA Prestige Health Choice)
  • AvMed
  • Blue Cross and Blue Shield HMO
  • Blue Cross and Blue Shield Non HMO
  • Blue Cross Blue Shield Florida Blue Select
  • Cigna & Great West HMO/POS Open Access
  • Cigna & Great West PPO/EPO
  • Community Care Plan Medicaid
  • Employers Health Network PPO
  • Evolutions Healthcare
  • First Health Aetna PPO/EPO
  • Florida Medicaid
  • Florida Medicare
  • Health First Health Plans
  • HEALTHSMART HLTH PLANS PPO ORL
  • HUMANA HEALTHY HORIZONS (FKA HUMANA MEDICAID)
  • Humana HMO/POS
  • Humana PPO/EPO
  • Molina Healthcare Medicaid
  • Multiplan PPO
  • Olympus Managed Healthcare PPO ORL
  • Prime Health Services PPO Specialty Florida
  • Seminole Tribe of Florida
  • Simply Healthcare Healthy Kids
  • Simply Healthcare Medicaid HMO
  • Star Healthcare Network
  • Sunshine SMI/CMS 19 & 21
  • Sunshine State Health Plan Medicaid
  • Three Rivers Provider Network
  • Tricare/Humana Military Health Services
  • United Healthcare Commercial Products
  • United Healthcare Community Plan Medicaid
  • Volusia Health Network PPO/EPO

Medical Interests

  • Cancer clinical trials
  • Clinical drug development

  • Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., & Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet Oncology, 21(4), 531-540. doi:10.1016/S1470-2045(19)30856-3

    View Full Publication
  • Janz, T. A., Nagasubramanian, R., & Wei, J. L. (2019a). A Survival Analysis of Pediatric Tonsillar Malignancies and Review of a Rare Case. International Journal of Pediatric Otorhinolaryngology, 118, 160-164. doi:10.1016/j.ijporl.2018.12.033

    View Full Publication
  • Janz, T. A., Nagasubramanian, R., & Wei, J. L. (2019b). Pediatric head and neck fibrosarcomas: A demographical, treatment, and survival analysis and review of a rare case. International Journal of Pediatric Otorhinolaryngology, 116, 92-96. doi:10.1016/j.ijporl.2018.09.031

    View Full Publication
  • DuBois, S. G., Laetsch, T. W., Federman, N., Turpin, B. K., Albert, C. M., Nagasubramanian, R., & Pappo, A. S. (2018). The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer, 124(21), 4241-4247. doi:10.1002/cncr.31701

    View Full Publication
  • Laetsch, T. W., DuBois, S. G., Mascarenhas, L., Turpin, B., Federman, N., Albert, C. M., & Hawkins, D. S. (2018). Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. The Lancet Oncology, 19(5), 705-714. doi:10.1016/S1470-2045(18)30119-0

    View Full Publication
  • Drilon, A., Laetsch, T. W., Kummar, S., Dubois, S. G., Lassen, U. N., Demetri, G. D., & Hyman, D. M. (2018). Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New England Journal of Medicine, 378(8), 731-739. doi:10.1056/NEJMoa1714448

    View Full Publication
  • Laetsch, T. W., Nagasubramanian, R., & Casanova, M. (2018). Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. Pediatric Blood and Cancer, 65(1). doi:10.1002/pbc.26593

    View Full Publication
  • Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., & Hyman, D. M. (2017). A next-generation TRK kinase inhibitor overcomes acquired resistance to prior trk kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discovery, 7(9), 963-972. doi:10.1158/2159-8290.CD-17-0507

    View Full Publication
  • Nagasubramanian, R., Wei, J., Gordon, P., Rastatter, J. C., Cox, M. C., & Pappo, A. (2016). Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatric Blood and Cancer, 63(8), 1468-1470. doi:10.1002/pbc.26026

    View Full Publication

  • English
  • Tamil